Becton Dickinson and (BDX) Coverage Initiated by Analysts at KeyCorp

Stock analysts at KeyCorp initiated coverage on shares of Becton Dickinson and (NYSE:BDX) in a report released on Friday. The brokerage set an “overweight” rating on the medical instruments supplier’s stock.

A number of other analysts have also recently commented on the stock. Piper Jaffray Companies restated a “buy” rating and issued a $213.00 price objective on shares of Becton Dickinson and in a research report on Tuesday, September 12th. Royal Bank of Canada restated a “hold” rating and issued a $210.00 price objective on shares of Becton Dickinson and in a research report on Wednesday, October 25th. Morgan Stanley upped their price objective on shares of Becton Dickinson and from $205.00 to $245.00 and gave the company an “equal weight” rating in a research report on Friday, November 3rd. Zacks Investment Research cut shares of Becton Dickinson and from a “hold” rating to a “sell” rating in a research report on Monday, October 9th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $245.00 target price on shares of Becton Dickinson and in a report on Friday, November 3rd. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Becton Dickinson and has a consensus rating of “Buy” and a consensus price target of $228.07.

Shares of Becton Dickinson and (BDX) opened at $220.99 on Friday. The company has a debt-to-equity ratio of 1.44, a current ratio of 5.58 and a quick ratio of 5.03. Becton Dickinson and has a 1 year low of $163.36 and a 1 year high of $229.68. The company has a market cap of $58,608.70, a price-to-earnings ratio of 47.52, a P/E/G ratio of 1.72 and a beta of 1.07.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating the Zacks’ consensus estimate of $2.37 by $0.03. Becton Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The business had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.14 billion. During the same quarter in the prior year, the company earned $2.12 EPS. The firm’s quarterly revenue was down 2.0% on a year-over-year basis. research analysts expect that Becton Dickinson and will post 10.63 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Becton Dickinson and by 8.5% during the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock worth $3,366,809,000 after buying an additional 1,353,780 shares during the last quarter. State Street Corp boosted its stake in shares of Becton Dickinson and by 3.5% during the 2nd quarter. State Street Corp now owns 10,270,221 shares of the medical instruments supplier’s stock worth $2,003,834,000 after buying an additional 342,873 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Becton Dickinson and by 4.0% during the 2nd quarter. Northern Trust Corp now owns 2,813,937 shares of the medical instruments supplier’s stock worth $549,028,000 after buying an additional 106,966 shares during the last quarter. Fiera Capital Corp boosted its stake in shares of Becton Dickinson and by 7.1% during the 2nd quarter. Fiera Capital Corp now owns 2,782,146 shares of the medical instruments supplier’s stock worth $542,825,000 after buying an additional 183,372 shares during the last quarter. Finally, Fundsmith LLP boosted its stake in shares of Becton Dickinson and by 0.3% during the 2nd quarter. Fundsmith LLP now owns 2,302,590 shares of the medical instruments supplier’s stock worth $449,258,000 after buying an additional 5,977 shares during the last quarter. Institutional investors own 87.72% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3126707/becton-dickinson-and-bdx-coverage-initiated-by-analysts-at-keycorp.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.